Leerink Partners Remains Bullish After traveling with Hologic (HOLX) Management

September 30, 2016 7:51 AM EDT
Get Alerts HOLX Hot Sheet
Price: $37.64 -1.39%

Rating Summary:
    15 Buy, 15 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 11 | Down: 23 | New: 30
Trade HOLX Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Leerink Partners reiterated an Outperform rating and $46.00 price target on Hologic (NASDAQ: HOLX) after traveling with management. Consistent with Street projections, Leerink models ~4% organic growth in FY17 and expects management will likely establish an initial FY17 guidance range that brackets this figure.

Analyst Richard Newitter commented, "HOLX remains a top mid/large-cap pick following recent diligence and time on the road with management. We have increased confidence HOLX can be a sustainable MSD top-line grower over the next several years with several underappreciated drivers beyond US 3D Tomo capital sales (OUS acceleration, R&D pipeline emphasis, 3D service rev), and more meaningful top-line acceleration into the out-years is a real possibility, especially when factoring in tuck-in M&A potential. We also continue to view HOLX as one of the more dependable double-digit (sustainable low-teens) EPS growth stories in MedTech with strong est. upside prospects, and an above-avg. 7% FCF yield. Reiterate OP & $46 PT."

For an analyst ratings summary and ratings history on Hologic click here. For more ratings news on Hologic click here.

Shares of Hologic closed at $38.14 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Add Your Comment